Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
0.4046
-0.0170 (-4.03%)
May 13, 2025, 4:00 PM - Market closed
Lyell Immunopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 0.07 | 0.06 | 0.13 | 84.68 | 10.65 | 7.76 | Upgrade
|
| Revenue Growth (YoY) | -4.41% | -53.08% | -99.85% | 695.15% | 37.31% | 1080.52% | Upgrade
|
| Gross Profit | 0.07 | 0.06 | 0.13 | 84.68 | 10.65 | 7.76 | Upgrade
|
| Selling, General & Admin | 52.59 | 52.04 | 66.98 | 117.31 | 89.06 | 46.88 | Upgrade
|
| Research & Development | 171.88 | 171.6 | 182.95 | 159.19 | 138.69 | 182.24 | Upgrade
|
| Other Operating Expenses | -3.68 | -4.65 | -4.3 | -4.86 | -3.53 | -1.65 | Upgrade
|
| Operating Expenses | 220.79 | 218.99 | 245.63 | 271.64 | 224.22 | 227.48 | Upgrade
|
| Operating Income | -220.73 | -218.93 | -245.5 | -186.96 | -213.57 | -219.72 | Upgrade
|
| Interest & Investment Income | 21.11 | 24.07 | 23.45 | 7.05 | 1.17 | 5.94 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.11 | 0.89 | 1.85 | 1.89 | 0.1 | 1.53 | Upgrade
|
| EBT Excluding Unusual Items | -198.5 | -193.98 | -220.2 | -178.02 | -212.31 | -212.26 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -13 | -12.92 | -5 | -36.7 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.34 | -1.34 | -1.51 | -0.1 | -1.21 | 4.88 | Upgrade
|
| Asset Writedown | -51.3 | -51.3 | - | - | - | - | Upgrade
|
| Other Unusual Items | 3.8 | 3.8 | - | - | - | 2.9 | Upgrade
|
| Pretax Income | -334.52 | -342.99 | -234.63 | -183.12 | -250.22 | -204.47 | Upgrade
|
| Net Income | -334.52 | -342.99 | -234.63 | -183.12 | -250.22 | -204.47 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 3.58 | Upgrade
|
| Net Income to Common | -334.52 | -342.99 | -234.63 | -183.12 | -250.22 | -208.05 | Upgrade
|
| Shares Outstanding (Basic) | 295 | 261 | 251 | 247 | 136 | 13 | Upgrade
|
| Shares Outstanding (Diluted) | 295 | 261 | 251 | 247 | 136 | 13 | Upgrade
|
| Shares Change (YoY) | 16.95% | 4.18% | 1.58% | 81.79% | 925.18% | 144.21% | Upgrade
|
| EPS (Basic) | -1.13 | -1.31 | -0.93 | -0.74 | -1.84 | -15.69 | Upgrade
|
| EPS (Diluted) | -1.13 | -1.31 | -0.93 | -0.74 | -1.84 | -15.69 | Upgrade
|
| Free Cash Flow | - | -162.86 | -166.38 | -193.83 | -191.75 | -212.36 | Upgrade
|
| Free Cash Flow Per Share | - | -0.62 | -0.66 | -0.78 | -1.41 | -16.02 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -339576.92% | -358906.56% | -188845.39% | -220.77% | -2005.31% | -2832.92% | Upgrade
|
| Profit Margin | -514649.23% | -562285.25% | -180486.15% | -216.24% | -2349.47% | -2682.49% | Upgrade
|
| Free Cash Flow Margin | - | -266980.33% | -127984.62% | -228.89% | -1800.50% | -2737.94% | Upgrade
|
| EBITDA | -201.21 | -199.3 | -225.25 | -168.94 | -199.94 | -215.43 | Upgrade
|
| EBITDA Margin | - | - | - | -199.49% | - | - | Upgrade
|
| D&A For EBITDA | 19.51 | 19.63 | 20.25 | 18.02 | 13.62 | 4.29 | Upgrade
|
| EBIT | -220.73 | -218.93 | -245.5 | -186.96 | -213.57 | -219.72 | Upgrade
|
| EBIT Margin | - | - | - | -220.77% | - | - | Upgrade
|
Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.